健康成人门诊社区获得性肺炎不同抗生素方案治疗的比较安全性
本研究为活性对照新用户队列研究(2007-2019年),纳入145 137例18-64岁无合并症、经胸部X线诊断的门诊CAP成人,比较不同口服抗生素方案的不良药物事件风险。与macrolide单药治疗相比,广谱方案与多种不良事件风险增加相关,窄谱方案风险大致相似;作者认为需抗菌药物管理促进广谱抗生素合理使用以减少相关不良事件。
要点
- 52%患者接受窄谱方案(44%大环内酯类,8%多西环素),48%接受广谱方案(39%氟喹诺酮类,7%β-内酰胺类,3%β-内酰胺类+大环内酯类)。
- 与macrolide单药相比,β-内酰胺类恶心的呕吐/腹痛风险差每1000例3.20(95%CI 0.99-5.73)。
- 与macrolide单药相比,β-内酰胺类非艰难梭菌腹泻风险差每1000例4.61(95%CI 2.47-6.82)。
核心结论
- 在门诊接受CAP治疗的无合并症健康成人中,广谱抗生素与不良药物事件风险增加相关。
- 作者认为需要抗菌药物管理以促进广谱抗生素的合理使用,并最终减少抗生素相关不良药物事件。
研究设计与样本
- 活性对照新用户队列研究,时间范围为2007-2019年。
- 纳入18-64岁、有商业保险、经胸部X线评估诊断的门诊CAP成人,且当日配发CAP相关口服抗生素方案。
- 共纳入145 137例无合并症的健康CAP患者。
- 不良药物事件随访时长为2至90天(例如肾衰竭为14天)。
- 采用倾向评分加权的Kaplan-Meier函数估计每1000次治疗的风险差和风险比。
主要发现
- 52%患者接受窄谱方案(44%大环内酯类,8%多西环素),48%接受广谱方案(39%氟喹诺酮类,7%β-内酰胺类,3%β-内酰胺类+大环内酯类)。
- 与macrolide单药治疗相比,每种广谱抗生素方案与多种不良药物事件风险增加相关。
- 与macrolide单药相比,β-内酰胺类的恶心/呕吐/腹痛风险差为每1000例3.20(95%CI 0.99-5.73)。
- 与macrolide单药相比,β-内酰胺类的非艰难梭菌(Clostridioides difficile)腹泻风险差为每1000例4.61(95%CI 2.47-6.82)。
- 与macrolide单药相比,β-内酰胺类的外阴阴道念珠菌病/阴道炎风险差为每1000例3.57(95%CI 0.87-6.88)。
临床怎么用
- 作者认为需要抗菌药物管理以促进广谱抗生素的合理使用,并最终减少抗生素相关不良药物事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence is limited on the comparative safety of antibiotic regimens for treatment of community-acquired pneumonia (CAP). We compared the risk of adverse drug events (ADEs) associated with antibiotic regimens for CAP treatment among otherwise healthy, nonelderly adults. METHODS: We conducted an active-comparator new-user cohort study (2007-2019) of commercially insured adults aged 18-64 years diagnosed with outpatient CAP, evaluated via chest X-ray, and dispensed a same-day CAP-related oral antibiotic regimen. ADE follow-up duration ranged from 2 to 90 days (eg, renal failure [14 days]). We estimated risk differences [RDs] per 1000 treatment episodes and risk ratios using propensity score-weighted Kaplan-Meier functions. Ankle/knee sprain and influenza vaccination were considered as negative control outcomes. RESULTS: Of 145 137 otherwise healthy CAP patients without comorbidities, 52% received narrow-spectrum regimens (44% macrolide, 8% doxycycline) and 48% received broad-spectrum regimens (39% fluoroquinolone, 7% β-lactam, 3% β-lactam + macrolide). Compared with macrolide monotherapy, each broad-spectrum antibiotic regimen was associated with increased risk of several ADEs (eg, β-lactam: nausea/vomiting/abdominal pain [RD per 1000, 3.20; 95% CI, 0.99-5.73]; non-Clostridioides difficile diarrhea [RD per 1000, 4.61; 95% CI, 2.47-6.82]; vulvovaginal candidiasis/vaginitis [RD per 1000, 3.57; 95% CI, 0.87, 6.88]). Narrow-spectrum antibiotic regimens largely conferred similar risk of ADEs. We generally observed similar risks of each negative control outcome, indicating minimal confounding. CONCLUSIONS: Broad-spectrum antibiotics were associated with increased risk of ADEs among otherwise healthy adults treated for CAP in the outpatient setting. Antimicrobial stewardship is needed to promote judicious use of broad-spectrum antibiotics and ultimately decrease antibiotic-related ADEs.
引用
- Butler AM, Nickel KB, Olsen MA, et al. Comparative Safety of Different Antibiotic Regimens for the Treatment of Outpatient Community-Acquired Pneumonia Among Otherwise Healthy Adults. Clin Infect Dis. 2026. PMID: 39442057. doi:10.1093/cid/ciae519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。